Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: a randomized, double-blind, placebo controlled study.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

To evaluate the ability of the new food supplement, Body Lipid (BL), containing red yeast rice, berberine, coenzyme Q10 and hydroxytyrosol, to lower the LDL-C in patients with mild-to-moderate hypercholesterolemia and to assess the overall safety profile of the product.

Who Took Part

The abstract describes 158 patients taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

In this multicenter, randomized, double-blind, placebo and active comparator (the marketed Armolipid Plus® [AM]) controlled study, 158 hypercholesterolemic patients were randomized following a 4-week dietary run-in period.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

Some patients received a placebo instead of Copper (Supplement), giving a reference point.

More than one site took part, so the patients came from several places.

What Was Measured

PubMed files the paper under topics including Anticholesteremic Agents, Biomarkers, Cholesterol, LDL, Dietary Supplements, Down-Regulation, Hypercholesterolemia and Italy.

Author keywords: berberine, coenzyme Q10, hydroxytyrosol, lipid profile and red yeast rice.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 158 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Drug design, development and therapy), a journal based in New Zealand.

More context: the Copper (Supplement) compound page, all human trials.